OC
IMUC

Oppenheimer & Co’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Oppenheimer & Co’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-250
Closed -$9K – 1585
2014
Q3 		$9K Hold
250
– – ﹤0.01% 1409
2014
Q2 		$11K Hold
250
– – ﹤0.01% 1401
2014
Q1 		$12K Sell
250
-2,425
-91% -$119K ﹤0.01% 1395
2013
Q4 		$99K Buy
+2,675
New +$253K ﹤0.01% 1317

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Oppenheimer & Co's IMUC Position: Q4 2014 in Review

Oppenheimer & Co sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2014, closing a stake of 250 shares — an estimated $9K sold.

Oppenheimer & Co first reported a position in IMUC in Q4 2013 and held it in 4 quarters. The position peaked at $99K in Q4 2013. 31 funds tracked by Wall St. Rank hold IMUC as of Q4 2014.

  • Oppenheimer & Co reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2014 after selling out during the quarter.
  • Oppenheimer & Co sold 250 ImmunoCellular Therapeutics, Ltd. shares in Q4 2014, an estimated $9K.
  • Oppenheimer & Co first reported a position in ImmunoCellular Therapeutics, Ltd. in Q4 2013 and held it in 4 quarters.
  • Oppenheimer & Co's ImmunoCellular Therapeutics, Ltd. position peaked at $99K in Q4 2013.
  • 31 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2014.

Based on Oppenheimer & Co's 13F filing for Q4 2014, filed 10 Feb 2015.